Peptide Schedule
MOTS-c16 residuesMRWQEMGYIFYPRKLREach bubble = one amino acid. Size = residue mass. Color = chemical class.MOTS-c
Benefits
About MOTS-c
MOTS-c is a mitochondria-derived peptide encoded in mitochondrial DNA — making it one of the few known mitochondrial-encoded signaling molecules. It acts as an 'exercise mimetic,' activating AMPK (the same pathway triggered by exercise) to improve metabolic function. Research shows it enhances insulin sensitivity, promotes fatty acid oxidation, and improves exercise capacity even without training.
Who Should Consider MOTS-c
- Adults with insulin resistance or prediabetes
- Aging individuals experiencing metabolic decline
- Those seeking exercise-like metabolic benefits during periods of inactivity
- Individuals with obesity or metabolic syndrome
- Researchers studying mitochondrial signaling and aging
How MOTS-c Works
MOTS-c is a 16-amino-acid peptide encoded within the 12S rRNA gene of the mitochondrial genome — one of the few known signaling molecules produced directly by mitochondrial DNA. Its primary mechanism involves inhibiting the folate cycle and its connected de novo purine biosynthesis pathway in skeletal muscle. This metabolic disruption triggers activation of AMP-activated protein kinase (AMPK), the same energy-sensing enzyme activated during physical exercise. Once AMPK is engaged, MOTS-c stimulates glucose uptake by promoting GLUT4 translocation to the cell membrane, increases fatty acid oxidation, and shifts cellular metabolism toward energy production rather than storage. Under conditions of metabolic stress — such as glucose restriction or oxidative challenge — MOTS-c translocates from the cytoplasm into the nucleus in an AMPK-dependent manner. Inside the nucleus, it binds to antioxidant response element (ARE) regions of DNA and interacts with the transcription factor NRF2 to regulate stress-response genes. This mitochondria-to-nucleus signaling represents a direct retrograde communication pathway, allowing mitochondria to influence nuclear gene expression during metabolic strain. Endogenous MOTS-c levels increase in skeletal muscle up to 12-fold following acute exercise in humans and decline with aging, correlating with age-related metabolic dysfunction.
What to Expect
Minimal noticeable effects. Some users report mildly increased energy levels. AMPK activation begins at the cellular level but outward changes are not yet apparent.
Improved exercise tolerance and endurance may become noticeable. Fasting glucose levels may begin trending downward. Mild increase in daily energy expenditure.
Measurable improvements in insulin sensitivity and fasting glucose. Enhanced fatty acid oxidation may contribute to modest changes in body composition. Exercise recovery time may decrease.
Peak metabolic benefits typically observed. Improved glucose regulation, better exercise capacity, and sustained energy levels throughout the day. Body composition improvements become more apparent.
Benefits gradually diminish over 2-4 weeks after discontinuation. Endogenous MOTS-c production continues but at baseline levels. Most users follow a 4-weeks-on, 2-weeks-off cycle pattern.
Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 5mg | 3x/week |
| Moderate | 10mg | 3x/week |
| Aggressive | 10mg | 5x/week |
Note: Mitochondria-derived peptide. Enhances AMPK activation and fatty acid oxidation. Commonly cycled 4 weeks on, 2 weeks off. May improve insulin sensitivity.
Pharmacokinetics
Source: Estimated from preclinical data; endogenous MOTS-c has an approximate t½ of 12-15 hours based on circulating peptide clearance studies
Loading the interactive decay curve.
Side Effects
Generally well-tolerated. Mild injection site reactions. Some users report increased energy that may affect sleep if dosed late.
Contraindications
- Pregnancy or breastfeeding
- Active hypoglycemia or insulin-dependent diabetes without physician oversight
- Known hypersensitivity to mitochondrial-derived peptides
- Children and adolescents (insufficient safety data)
- Severe hepatic impairment (MOTS-c is being studied in hepatic steatosis — use only under clinical supervision)
Drug Interactions
- Metformin and other AMPK activators — potential additive effect on glucose lowering and AMPK signaling; monitor for hypoglycemia
- Insulin and sulfonylureas — combined insulin-sensitizing effects may increase hypoglycemia risk
- Folate supplements and antifolates (methotrexate) — MOTS-c inhibits the folate cycle, which could alter drug efficacy or toxicity
- Thiazolidinediones (pioglitazone, rosiglitazone) — overlapping insulin-sensitizing pathways may produce additive effects
Molecular Profile
Related Peptides
References
- The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance (Lee et al. 2015)PubMed 25738459
- The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress (Kim et al. 2018)PubMed 29983246
- MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis (Reynolds et al. 2021)PubMed 33473109
- Plasma MOTS-c levels are associated with insulin sensitivity in lean but not in obese individuals (Cataldo et al. 2018)PubMed 29593067
- MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism (Ming et al. 2016)PubMed 27216708
- MOTS-c: the most recent mitochondrial derived peptide in human aging and age-related diseases (Mohtashami et al. 2022)PubMed 36233287